Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1524 participants.

Also called NCT07687706

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 1,524 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07687706
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07687706. Randomized; triple masking; primary purpose prevention. Start 2026-01-26 (actual); primary completion 2027-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)
Acronym
TegoStroke
Condition
Ischemic Stroke, Acute
Condition
Cerebrovascular Disease
Condition
Gastrointestinal Complication
Condition
Gastrointestinal Bleeding
Intervention (Drug)
Tegoprazan 50 mg
Intervention (Drug)
Placebo
Lead sponsor
Hanyang University Guri Hospital (class: other)
Collaborator
HK inno.N Corporation (class: industry)

Record details

Record id
cardio:ct-nct07687706
Content hash
9d065b0b2eb756c5244a7366cfc86ac022b5d6fddab2e94d35705b6b0af41415